October 2010

 

OPHTHALMOLOGY NEWS

 

Allergan receives FDA approval for glaucoma treatment


   

The Federal Drug Administration has approved Allergan, Inc.'s, Lumigan 0.01%, a therapy that reduces elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Lumigan is a once-daily prescription eye drop. In a three-month study of patients with open-angle glaucoma or ocular hypertension with an average baseline of 23.5 mm Hg, it lowered pressure up to 7 mm Hg from baseline, with only one-third the drug exposure. "Once-a-day prostaglandins are becoming a therapy of choice based on their efficacy, systemic safety, and ease of use," said L. Jay Katz, M.D., director of the glaucoma service at Wills Eye Hospital and professor of ophthalmology at Jefferson Medical College. "Based on its efficacy and tolerability, Lumigan 0.01% should be considered early in the treatment continuum as an alternative to other prostaglandins or therapies."

"The approval of Lumigan 0.01% provides doctors with an efficacious, safe, and well-tolerated IOP-lowering medication for glaucoma patients who are either starting treatment or are changing their medication regimen," said Scott Whitcup, M.D., Allergan's chief scientific officer, in a statement. "Lumigan 0.01% exemplifies Allergan's commitment to developing medications for glaucoma patients that maximize efficacy while minimizing drug exposure."

The most common side effects of the eye drops are hyperemia, eyelash growth, and ocular pruritis. It's expected to be available in fourth quarter 2010.

Reported by: EyeWorld News Service

Allergan receives FDA approval for glaucoma treatment Allergan receives FDA approval for glaucoma treatment
Ophthalmology News - EyeWorld Magazine
283 110
283 110
,
2016-08-01T13:44:13Z
True, 10